Effects of efonidipine on the pharmacokinetics and pharmacodynamics of repaglinide: Possible role of CYP3A4 and P-glycoprotein inhibition by efonidipine

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 39, Issue 1, 2012, Pages 99-108

  Li, Cheng ^a,b   Choi, Dong Hyun ^a   Choi, Jun Shik ^a  

^a Chosun University   (South Korea)

^b YANBIAN UNIVERSITY   (China)

Author keywords

CYP3A4; Efonidipine; P gp; Pharmacodynamics; Pharmacokinetics; Rat; Repaglinide

Indexed keywords

CYTOCHROME P450 3A4; EFONIDIPINE; GLUCOSE; GLYCOPROTEIN P; KETOCONAZOLE; REPAGLINIDE;

ANIMAL EXPERIMENT; ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; IC 50; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; BIOCATALYSIS; BIOLOGICAL AVAILABILITY; BLOOD GLUCOSE; CARBAMATES; CELL LINE, TUMOR; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DIHYDROPYRIDINES; DRUG INTERACTIONS; HUMANS; HYPOGLYCEMIC AGENTS; KETOCONAZOLE; MALE; MODELS, BIOLOGICAL; NITROPHENOLS; ORGANOPHOSPHORUS COMPOUNDS; P-GLYCOPROTEIN; PHARMACOLOGICAL PHENOMENA; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RHODAMINE 123;

EID: 84861483932     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-011-9234-0     Document Type: Article

References (33)

1. Hatorp V (2002) Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin Pharmacokinet 41:471-483
2. Gromada J, Dissing S, Kofod H, Frokjaer-Jensen J (1995) Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium-channels and cytosolic 113 calcium levels in beta TC3 cells and rat pancreatic beta cells. Diabetologia 38:1025-1032
3. Ruzilawati AB, Wahab MS, Imran A, Ismail Z, Gan SH (2007) Method development and validation of repaglinide in human plasma by HPLC and its application in pharmacokinetic studies. J Pharm Biomed Anal 43:1831-1835 (Pubitemid 46453063)
4. Culy CR, Jarvis B (2001) Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. Drugs 61:1625-1660 (Pubitemid 32905281)
5. Bidstrup TB, Bjurnsdottir I, Sidelmann UG, Thomsen MS, Hansen KT (2003) CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. Br J Clin Pharmacol 56:305-314 (Pubitemid 37059658)
6. Bauer E, Beschke K, Ebner T, Greischel A (1997) Biotransformation of [14C] repaglinide in human, cynomolgus monkey, dog, rabbit, rat and mouse. Diabetologia 40(1):326-332
7. Chang C, Bahadduri PM, Polli JE, Swaan PW, Ekins S (2006) Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab Dispos 34:1976-1984 (Pubitemid 44837758)
8. Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT (2005) Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther 78:388-399 (Pubitemid 41393674)
9. Nakabeppu H, Asada M, Oda T, Shinozaki Y, Yajima T (1996) Plasma and urinary metabolites of efonidipine hydrochloride in man. Xenobiotica 26:229-239 (Pubitemid 26103648)
10. Masuda Y, Takeguchi M, Arakawa C, Sakai T, Hibi M, Tanaka S, Shigenobu K, Kasuya Y (1990) Antihypertensive and diuretic effects of NZ-105, a novel dihydropyridine derivative. Arch Int Pharmacodyn Ther 304:247-264 (Pubitemid 20275312)
11. Tamura T, Saigusa A, Kokubun S (1991) Mechanisms underlying the slow onset of action of a new dihydropyridine, NZ-105, on a cultured smooth muscle cell line. Naunyn Schmiedebergs Arch Pharmacol 343:405-410
12. Tanaka T, Tsutamoto T, Sakai H, Fujii M, Yamamoto T, Horie M (2007) Comparison of the effects of efonidipine and amlodipine on aldosterone in patients with hypertension. Hypertens Res 30:691-697 (Pubitemid 47517102)
13. Shimizu M, Ogawa K, Sasaki H, Uehara Y, Otsuka Y, Okumura H, Kusaka M, Hasuda T, Yamada T, Mochizuki S (2003) Effects of efonidipine, an L- and T-Type dual calcium channel blocker, on heart rate and blood pressure in patients with mild to severe hypertension: an uncontrolled, open-label pilot study. Curr Ther Res 64:707-714 (Pubitemid 38130686)
14. Yoon SS, Mekalanos JJ (2006) 2,3-butanediol synthesis and the emergence of the Vibrio cholerae El Tor biotype. Infect Immun 74:6547-6556 (Pubitemid 44913129)
15. Crespi CL, Miller VP, Penman BW (1997) Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal Biochem 248:188-190 (Pubitemid 27218241)
16. Han CY, Cho KB, Choi HS, Han HK, Kang KW (2008) Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells. Carcinogenesis 29:1837-1844
17. Fuhlendorff J, Rorsman P, Kofod H, Brand CL, Rolin B, MacKay P, Shymko R, Carr RD (1998) Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 47:345-351 (Pubitemid 28104194)
18. Gonzalez FJ (1993) Cytochrome P450 in humans. In: Schenkman JB, Grein H (eds) Cytochrome P450: handbook of experimental pharmacology vol. 105. Springer-Verlag, Berlin
19. Li AP, Kaminski DL, Rasmussen A (1995) Substrates of human hepatic cytochrome P450 3A4. Toxicology 104:1-8 (Pubitemid 26016371)
20. Wrighton SA, Stevens JC (1992) The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 22:1-21
21. Sutherland L, Ebner T, Burchell B (1993) The expression of UDP-glucuronosyltransferases of the UGT1 family in human liver and kidney and in response to drugs. Biochem Pharmacol 45:295-301 (Pubitemid 23042627)
22. Turgeon D, Carrier JS, Lévesque E, Hum DW, Bélanger A (2001) Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology 142:778-787 (Pubitemid 32222427)
23. Watkins PB (1996) The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 27:161-170
24. Wacher VJ, Silverman JA, Zhang Y, Benet LZ (1998) Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 87: 1322-1330
25. Kelly PA, Wang H, Napoli KL, Kahan BD, Strobel HW (1999) Metabolism of cyclosporine by cytochromes P450 3A9 and 3A4. Eur J Drug Metab Pharmacokinet 24:321-328 (Pubitemid 30342700)
26. Bogaards JJ, Bertrand M, Jackson P, Oudshoorn MJ, Weaver RJ, van Bladeren PJ, Walther B (2000) Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 30:1131-1152 (Pubitemid 32368013)
27. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, Waxman DJ (1986) Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 261:5051-5060 (Pubitemid 17204301)
28. Lewis DFV (1996) Cytochrome P450. Substrate specificity and metabolism. Cytochromes P450. Structure, function, and mechanism. Taylor & Francis, Bristol, pp. 122-123
29. Cao X, Gibbs ST, Fang L, Miller HA, Landowski CP, Shin HC, Lennernas H, Zhong Y, Amidon GL, Yu LX, Sun D (2006) Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res 23:1675-1686 (Pubitemid 44200529)
30. Kivistö KT, Bookjans G, Formm MF, Griese EU, Munzel P, Kroemer HK (1996) Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue. Br J Clin Pharmacol 42: 387-389 (Pubitemid 26284429)
31. Zhang QY, Dunbar D, Ostrowska A, Zeisloft S, Yang J, Kaminsky LS (1999) Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos 27:804-809 (Pubitemid 29297778)
32. Niemi M, Neuvonen PJ, Kivistö KT (2001) The cytochrome P450 3A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther 70:58-65 (Pubitemid 32678803)
33. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ (2003) Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 46:347-351 (Pubitemid 36547589)